Tarceva came before the CDR when I was the CEDAC chair, and to the best of my recollection, it was dealt with in the five months' time process, and to the best of my recollection it was recommended for funding under certain criteria.
I don't know whether those criteria were the ones your mom would have had, but certainly, to my knowledge, it wasn't delayed.
Is one allowed to make a comment?
I think the question raises one of the issues I talk about, which is the lack of integration within the whole system. I think for drugs that are truly advances, one would like to have CDR starting to review the drug at the same time as Health Canada is reviewing it, so that they don't have to wait all that time and then start all over again.
My understanding is that the CDR has started to have a few pilot tries at looking at the information that's provided to Health Canada. That can only happen, obviously, with the drug company's approval. That would be another example of the lack of integration, which does lead to a longer time than it probably should take.